glp 1 fda approved In a major milestone for obesity care, the has Wegovy® as the first oral GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight and related conditions FDA Approves First Generic GLP-1

The SELECT trial , published in the New England Journal of Medicine and conducted across 804 sites in 41 countries with 17,604 participants, showed semaglutide reduced major adverse cardiovascular events by 20% in people with obesity but without diabetes

PlexusDx supports this precision approach by integrating genetic insights into patient conversations about GLP-1/GIP therapy

Retrieved 12 February 2024

Early research suggests this effect accounts for 2-4% of additional weight loss beyond what dual agonism achieves, a number that compounds significantly over a 48 to 68 week treatment period

Furthermore, in a Phase 1 randomized, double-blind, placebo-controlled clinical study (NCT04478708) in patients with obesity, adult obese subjects received either a single ascending dose (SAD) or multiple ascending doses (MAD) of AMG 133, compared with a placebo group

GLP-1 medications have been extensively studied